Retrospective Observational Study of Acute Subdural Hematoma Treated with Idarucizumab in Japa
Not Applicable
- Conditions
- Acute Subdural Hematoma
- Registration Number
- JPRN-UMIN000047782
- Lead Sponsor
- International University of Health and Welfare, School of Medicine
- Brief Summary
The frequency of decreased consciousness level during the course was 30.4%. Among them, the frequency of decreased consciousness level was 14.3% in cases in which the reversal agent was administered early before deterioration of consciousness level and imaging findings was observed. Three patients (13.1%) had ischemic complications. The timing of onset of ischemic complications was 7 days or more after the administration of the reversal agent and before the resumption of anticoagulant in all patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 23
Inclusion Criteria
Not provided
Exclusion Criteria
1. Multiple trauma cases including trauma to other sites with AIS > 3 2. Cases with coexisting chronic subdural hematoma 3. Cases of cardiopulmonary arrest at the time of delivery
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Frequency of ischemic complications after reversal therapy
- Secondary Outcome Measures
Name Time Method